Foghorn Therapeutics Inc. (FHTX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US3441741077
Foghorn Therapeutics Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 30.91 m USD |
| Operating income | -86.39 m USD |
| EBIT | -74.28 m USD |
| Net income | -74.28 m USD |
| Diluted EPS – continuing operations | -1.18 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
More stocks
- Jw Life Science Corp (234080.KS)
- EI Power Berhad (0453.KL)
- SPRUCE BIOSCIENCES, INC. (SPRB)
- EASY BIOInc (353810.KQ)
- Excelliance MOS (5299.TWO)
- Helixmith Co. Ltd (084990.KQ)
- Lucara Diamond Corp (LUC.TO)
- MAXCYTE, INC. (MXCT)
- Compagnie Lebon S.A. (ALBON.PA)
- STLLR Gold Inc. (STLR.TO)
- WW INTERNATIONAL, INC. (WW)
- Jyong Biotech Ltd. Ordinary Shares (MENS)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.